Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds



Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And
                            Novartis Venture Funds

  PR Newswire

  SAN DIEGO, Oct. 30, 2012

SAN DIEGO, Oct. 30, 2012 /PRNewswire/ -- Thesan Pharmaceuticals announced the
closing of a $16M Series A financing, co-led by Novo Ventures and Novartis
Venture Funds.  The company will focus on the development of novel approaches
for the treatment of dermatological disorders. The lead drug candidate is a
topically-applied new chemical entity expected to enter the clinic in 2013.

"For many years, drug development in the dermatology field has been dominated
by old drugs just re-formulated into more cosmetically appealing foams, gels
or lotions," said Gordon Foulkes, Thesan's Executive Chairman and CEO.
"Thesan's mission is to develop new chemical entities with novel mechanisms of
action in order to substantially improve treatment outcomes for patients with
a variety of dermatological diseases." 

The company's first products have been licensed from the University of
California, Irvine (UCI). The products have been developed in the laboratory
of Professor Daniele Piomelli, who is Louise Turner Arnold Chair of
Neurosciences at UCI and the Director of Drug Discovery and Development at the
Istituto Italiano di Tecnologia (IIT), Genoa, Italy.  

"We are very pleased to be part of the investor syndicate behind Thesan," said
Peter Bisgaard, Partner at Novo Ventures. "We believe Professor Piomelli's
work offers a unique opportunity for developing a completely new class of
anti-inflammatory agents, which can be moved rapidly into clinical
development. Further, we look forward to working with Professor Piomelli and
Thesan management to build the pipeline of future candidates."

"This is an extremely exciting opportunity to move toward the clinic the first
technology born from the long-standing international collaboration between UCI
and the IIT," said Professor Piomelli. "Our collaboration to develop
therapeutic candidates has been validated by our ability to attract such a
strong management team and group of investors to further commercialize our
laboratories' efforts."

"A novel mechanism of action with dramatic efficacy, coupled with such solid
chemistry is a great starting point for the formation of a new company," said
Giovanni Ferrara, Venture Partner at Novartis Venture Funds.  "Combined with a
world class team, it made for a compelling investment." 

In connection with the financing, Peter Bisgaard and Tiba Aynechi from Novo,
as well as Giovanni Ferrara and Henry Skinner from Novartis have joined the
company's Board, along with Dr. Howard Welgus, former VP R&D for
Dermatology/Inflammation at Pfizer.  

About Thesan Pharmaceuticals, Inc.

Thesan is a newly formed, venture capital-funded biotechnology company focused
on the development and commercialization of novel drugs for the treatment of
dermatological conditions. For more information visit:  www.ThesanPharma.com

About Novo Ventures

Novo is the holding company of the Novo Group, and is wholly owned by the Novo
Nordisk Foundation. It was established in 1999 to manage the assets of the
foundation and actively make investments on its behalf. Novo Ventures focuses
on life sciences venture capital, and is active in both Europe and North
America. The firm has four partners in Copenhagen, one in London and three in
San Francisco. With an evergreen structure, it annually invests approximately
$100M in venture capital into private life sciences companies. For more
information, visit: www.novo.dk

About Novartis Venture Funds

Founded in 1996, the Novartis Venture Funds currently manage over $800 million
in committed capital. As a financially driven corporate life science investor,
the Novartis Venture Funds invest in those companies which have the potential
to address significant unmet medical needs critical to patient care. The
Novartis Venture Funds' team of ten investment professionals located in Basel
Switzerland and Cambridge, MA brings together extensive expertise in the
biotechnology, pharmaceutical and venture capital industries. For more
information, visit: www.venturefund.novartis.com

About UCI

Located in the heart of Orange County, UCI is among the fastest-growing
University of California campuses, is a member of the prestigious Association
of American Universities (AAU), and is consistently ranked among the nation's
best universities, public and private.  The Office of Technology Alliances at
UCI manages over 900 active university inventions and has licensed founding
technologies to more than 50 startup companies.

About IIT

The Istituto Italiano di Tecnologia is a private law Foundation jointly
established by the Ministry of Education, University and Research and the
Ministry of Economy and Finance, with the aim of promoting excellence in both
basic and applied research and to facilitate the development of the national
economy. IIT's total staff is comprises of over 1000 individuals. In Genoa,
the collaborating departments include Robotics ("Robotics, Brain and Cognitive
Sciences and "Advanced Robotics"), "Neuroscience and Brain Technologies; "Drug
Discovery and Development" and Nanotechnology.   

Contact:J. Gordon Foulkes, Ph.D.Chairman and Chief Executive OfficerThesan
Pharmaceuticals, Inc. info@thesanpharma.com

Website: http://www.thesanpharma.com
Website: http://www.novo.dk
Website: http://www.venturefund.novartis.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement